ADARx Pharmaceuticals, Inc. (ADRX) Income Statement
ADRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsADRX revenue and net income
Where ADRX's revenue goes
2025Each bar shows an amount and its share of revenue. ADRX kept −2,119.1% of revenue as net income.
ADRX profit margins
ADRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ADRX income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $3.4M | $0 |
| Research & development | $71.5M | $43.4M |
| Sales, general & admin | $20.3M | $14.9M |
| Total operating expenses | $91.8M | $58.2M |
| Operating income | −$88.4M | −$58.2M |
| Interest income | $13.6M | $11.4M |
| Income before taxes | −$73.1M | −$46.4M |
| Net income | −$73.1M | −$46.4M |
| EBITDA | −$86.0M | −$56.7M |
| Operating margin | −2,562.0% | — |
| Net margin | −2,119.1% | — |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $746,000 | $2.1M | $208,000 | $0 |
| Research & development | $24.7M | $23.6M | $17.1M | $12.9M |
| Sales, general & admin | $5.9M | $5.6M | $4.3M | $5.0M |
| Total operating expenses | $30.6M | $29.2M | $21.3M | $17.9M |
| Operating income | −$29.9M | −$27.1M | −$21.1M | −$17.9M |
| Interest income | $3.8M | $4.0M | $2.5M | $2.3M |
| Income before taxes | −$25.8M | −$22.7M | −$18.1M | −$15.6M |
| Net income | −$25.8M | −$22.7M | −$18.1M | −$15.6M |
| EBITDA | −$29.2M | −$26.3M | −$20.5M | −$17.4M |
| Operating margin | −4,006.8% | −1,264.3% | −10,154.8% | — |
| Net margin | −3,452.9% | −1,059.2% | −8,698.6% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ADRX's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ADRX financial results
In fiscal year 2025 (ended December 31, 2025), ADARx Pharmaceuticals reported revenue of $3.4 million. It had a net loss of $73.1 million, a net profit margin of −2,119.1%.
See the ADRX stock overview for the latest quote and news, or the ADRX chart for price history and technical indicators.
ADRX income statement FAQ
What is ADARx Pharmaceuticals's annual revenue?
ADARx Pharmaceuticals reported total revenue of $3.4 million for fiscal year 2025, which ended on December 31, 2025.
Is ADARx Pharmaceuticals profitable?
No. ADARx Pharmaceuticals reported a net loss of $73.1 million in fiscal 2025, a net profit margin of −2,119.1%; its operating margin was −2,562.0%.
How much does ADARx Pharmaceuticals spend on research and development?
ADARx Pharmaceuticals spent $71.5 million on research and development in fiscal 2025, 2,073.4% of revenue.
When does ADARx Pharmaceuticals's fiscal year end?
ADARx Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.